# XENON PHARMACEUTICALS INC (XENE)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/XENE/

- Reporting holders: 5
- Reported value: $443.4K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Wedmont Private Capital](https://holderbook.com/funds/1904274-wedmont-private-capital/) | $407.7K | 11,275 | 0.0% | 1 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $30.9K | 830 | 0.0% | 12 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $3.6K | 96 | 0.0% | 6 |
| [MassMutual Private Wealth & Trust, FSB](https://holderbook.com/funds/1103653-massmutual-private-wealth-trust-fsb/) | $669 | 18 | 0.0% | 4 |
| [CoreCap Advisors, LLC](https://holderbook.com/funds/1902501-corecap-advisors-llc/) | $632 | 17 | 0.0% | 4 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 5 | $443.4K |
| Q2 2026 | 322 | $6.4B |
| Q1 2026 | 297 | $6.1B |
| Q4 2025 | 255 | $3.9B |
| Q3 2025 | 223 | $3.5B |
| Q2 2025 | 207 | $2.6B |
| Q1 2025 | 211 | $2.6B |
| Q4 2024 | 212 | $3.0B |
| Q3 2024 | 206 | $3.0B |
| Q2 2024 | 213 | $2.9B |
| Q1 2024 | 223 | $3.3B |
| Q4 2023 | 213 | $3.5B |